The European Commission has granted marketing authorization to Indianapolis-based Elanco Animal Health and Kansas-based Aratana Therapeutics Inc. (Nasdaq: PETX) for a new veterinary medicine treatment. Elanco says the approval will allow the companies to market the drug Galliprant in the European Union.

Galliprant is prescribed to treat pain associated with mild-to-moderate osteoarthritis in dogs. Elanco has exclusive rights to develop, manufacture, market and commercialize the drug globally. The company co-promotes Galliprant with Aratana in the United States.

Elanco Animal Health is a division of Eli Lilly and Co. (NYSE: LLY) in Indianapolis.